3E0 Stock Chart & Stats
€79.92
-€1.26(-1.55%)
At close: 4:00 PM EDT
€79.92
-€1.26(-1.55%)
Day’s Range― - ―
52-Week Range€28.40 - €83.28
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€1.95B
Enterprise Value€2.78K
Total Cash (Recent Filing)€71.16M
Total Debt (Recent Filing)€263.67M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 10, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding29,801,891
10 Day Avg. Volume0
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)91.68
Price to Sales (P/S)10.23
P/FCF Ratio-37.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€88.26Price Target Upside10.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.04
Revenue Forecast (FY)€233.95M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & U.S. TractionRapid, sustained revenue acceleration and outsized U.S. adoption materially expand the company’s addressable market. A durable shift toward higher U.S. mix diversifies revenue, scales higher-margin channels, and supports long-term commercial leverage if surgeon certification and order trends continue.
High Gross Margins & Improving ProfitabilityConsistently high gross margins provide structural operating leverage, enabling the company to cover elevated SG&A while moving toward profitability. Margin expansion plus consecutive positive adjusted EBITDA quarters creates a durable path to sustained operating cash generation if revenue growth persists.
Product Differentiation & Clinical EvidenceBest-in-class clinical safety and warranty performance build a lasting competitive moat in elective medical devices. Clear surgeon preference and strong patient satisfaction underpin pricing power, higher procedure uptake and long-term brand advantage versus peers with higher complication rates.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow requires external funding or draw on facilities until consistent cash conversion is achieved. While burn has improved, continued negative cash generation creates execution risk and raises reliance on capital markets or debt to fund growth over the next several quarters.
Elevated Operating ExpensesHigh fixed and scaling SG&A consumes much of revenue upside and can delay durable profitability if growth slows. Structural expense discipline and operating leverage are required to convert strong gross margins into sustainable net income and cash flow as the U.S. rollout continues.
Reliance On Debt Facility With PIK MechanicsUse of a larger facility with payment-in-kind (PIK) accruals improves near-term liquidity but compounds future interest-bearing obligations if targets slip. Reliance on PIK-backed flexibility raises structural leverage risk and could constrain capital allocation or force refinancing under adverse conditions.
Establishment Labs Holdings News
3E0 FAQ
What was Establishment Labs Holdings Inc’s price range in the past 12 months?
Establishment Labs Holdings Inc lowest stock price was €28.40 and its highest was €83.28 in the past 12 months.
What is Establishment Labs Holdings Inc’s market cap?
Establishment Labs Holdings Inc’s market cap is €1.95B.
When is Establishment Labs Holdings Inc’s upcoming earnings report date?
Establishment Labs Holdings Inc’s upcoming earnings report date is Nov 10, 2026 which is in 87 days.
How were Establishment Labs Holdings Inc’s earnings last quarter?
Establishment Labs Holdings Inc released its earnings results on Aug 06, 2026. The company reported -€0.338 earnings per share for the quarter, missing the consensus estimate of -€0.292 by -€0.046.
Is Establishment Labs Holdings Inc overvalued?
According to Wall Street analysts Establishment Labs Holdings Inc’s price is currently Undervalued.
Does Establishment Labs Holdings Inc pay dividends?
Establishment Labs Holdings Inc does not currently pay dividends.
What is Establishment Labs Holdings Inc’s EPS estimate?
Establishment Labs Holdings Inc’s EPS estimate is -0.23.
How many shares outstanding does Establishment Labs Holdings Inc have?
Establishment Labs Holdings Inc has 29,801,891 shares outstanding.
What happened to Establishment Labs Holdings Inc’s price movement after its last earnings report?
Establishment Labs Holdings Inc reported an EPS of -€0.338 in its last earnings report, missing expectations of -€0.292. Following the earnings report the stock price went down -2.896%.
Which hedge fund is a major shareholder of Establishment Labs Holdings Inc?
Currently, no hedge funds are holding shares in DE:3E0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Establishment Labs Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€88.26 (10.43% Upside)
€88.26 (10.43% Upside)
Blogger Sentiment
Bullish
DE:3E0 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €7.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.30%
Trailing 12-Months
Company Description
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
3E0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and commercial momentum led by a rapid U.S. launch, 45% YoY revenue growth in Q1, improving gross margin (70.7%) and a return to positive adjusted EBITDA. Key product innovations (minimally invasive platform) are driving adoption, surgeon and patient demand, and management raised full-year revenue guidance. Offsetting factors include elevated operating expenses, near-term cash usage and increased debt with PIK mechanics, plus some supply and geopolitical uncertainties. Overall, the positives around revenue acceleration, margin expansion, product differentiation and pathway to cash-flow positivity materially outweigh the risks discussed.View all DE:3E0 earnings summaries3E0 Stock 12 Month Forecast
Average Price Target
€88.26
▲(10.43% Upside)